Herceptin: mechanisms of action and resistance

Rita Nahta(The University of Texas MD Anderson Cancer Center), Francisco J. Esteva(The University of Texas MD Anderson Cancer Center)

Cancer Letters

March 30, 2005

10.1016/j.canlet.2005.01.041

Cited by 441

Abstract

Related Papers

2000 Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology*

Robert C. Bast, Peter M. Ravdin, Daniel F. Hayes et al.|Journal of Clinical Oncology|2001|885

Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.

Alicia M. Viloria Petit, Janusz Rak, Mien‐Chie Hung et al.|PubMed|1997|841

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.

Michael F. Press, Leslie Bernstein, P. Thomas et al.|Journal of Clinical Oncology|1997|810

Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells.

Robert M. Hudziak, Joseph Schlessinger, Axel Ullrich|Proceedings of the National Academy of Sciences|1987|630

Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.

F. Michael Yakes, Wichai Chinratanalab, Christoph A. Ritter et al.|PubMed|2002|617